Smarter Phase 3 Decisions Start Earlier

From Early Data to Confident Phase 3 Decisions

Dear David,

Early development decisions have lasting consequences. Choices made well before Phase 3, around trial design, target product profile, and evidence strategy, can meaningfully shape downstream access, reimbursement, and commercial viability.

In this live webinar, experts from Certara will explore how advanced modeling approaches, including model-based meta-analysis (MBMA) and quantitative systems pharmacology (QSP), can inform high-impact decisions earlier in development—when strategies are still flexible and risk can be actively managed.

Participants will learn how advanced modeling can help HEOR teams: 

Inform Phase 3 go/no-go decisions with greater confidence 
Design Phase 3 studies that better support future reimbursement needs
Make strategic choices earlier using limited early-phase data
Strengthen alignment between development strategy and payer expectations

Register to access expert insights on early-phase decision-making and Phase 3 strategy.

Don’t want to receive these emails? No problem, simply click on the Unsubscribe link below.

By accessing this content, you are permitting Pharma Ignite or a third party to contact you regarding the content (by phone or email).